INT89701

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2000
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 0.92
Pain Relevance 2.23

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP2A6) endoplasmic reticulum (CYP2A6) enzyme binding (CYP2A6)
Anatomy Link Frequency
liver 1
CYP2A6 (Homo sapiens)
Pain Link Frequency Relevance Heat
Codeine 6 97.84 Very High Very High Very High
pregabalin 78 97.68 Very High Very High Very High
addiction 22 93.80 High High
Dextromethorphan 2 92.52 High High
alcohol 4 92.16 High High
Nicotine 19 89.68 High High
Central nervous system 2 89.52 High High
gABA 5 86.32 High High
Bioavailability 1 73.68 Quite High
Gabapentin 3 72.44 Quite High
Disease Link Frequency Relevance Heat
Nicotine Addiction 134 97.04 Very High Very High Very High
Disorders Of Creatine Metabolism 1 79.20 Quite High
Drug Dependence 4 75.00 Quite High
Anxiety Disorder 33 70.00 Quite High
Attention Deficit Hyperactivity Disorder 1 52.28 Quite High
Convulsion 36 50.52 Quite High
Epilepsy 24 50.00 Quite Low
Generalized Anxiety Disorder 21 44.96 Quite Low
Parkinson's Disease 1 20.24 Low Low
Alcohol Addiction 1 19.04 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
With respect to CYP2A6, individuals with mutations, smoke fewer cigarettes and can quit more easily.
CYP2A6 Binding (quit) of
1) Confidence 0.36 Published 2000 Journal Ann. N. Y. Acad. Sci. Section Abstract Doc Link 10911933 Disease Relevance 0.28 Pain Relevance 0.84
The cytochrome P450 results may have been driven by association between SNPs at CYP2B6 with EVNV, and CYP2A6 and SMKAGE (Table 3).
CYP2A6 Binding (association) of
2) Confidence 0.29 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2644817 Disease Relevance 0.32 Pain Relevance 0.18
Moreover, pregabalin dose not exhibit any significant protein binding, has no known drug interactions and, even at high doses, does not interact with CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, or CYP3A4 systems in vivo (Pfizer Inc. 2006).
CYP2A6 Neg (not) Binding (interact) of associated with pregabalin
3) Confidence 0.21 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654629 Disease Relevance 0.27 Pain Relevance 1.07
The activity of CYP1A2, CYP2A6, CYP2B6, CYP2D6, CYP2E1, CYP3A4, and CYP2C9 was not affected, and only a moderate inhibitory effect on CYP2C19 (by 38%), as well as a moderate increment of UDP-glucuronosyl-transferase 1A1-mediated ethinylestradiol glucuronidation (by 39%), was seen in the presence of ESL in human liver microsomes in vitro.36

In vivo studies

CYP2A6 Binding (activity) of in liver
4) Confidence 0.16 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2987506 Disease Relevance 0.05 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox